Showing results (41-50 of 68) with videos related to
Sort By:
Pageof 7
Pediatrics|August 18, 2018
Recruitment and Retention of Community PreceptorsMichael S Ryan, Lisa E Leggio, Christopher B Peltier, et al.Academic Medicine : Journal of the Association of American Medical Colleges|October 19, 2019
Women's Representation Among Members and Leaders of National Medical Specialty SocietiesReshma Jagsi, Olivia Means, Diana Lautenberger, et al.Human Vaccines & Immunotherapeutics|December 9, 2014
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trialMark H Einstein, Peter Takacs, Archana Chatterjee, et al.Human Vaccines|August 18, 2009
Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 yearsMark H Einstein, Mira Baron, Myron J Levin, et al.Journal of Inorganic Biochemistry|June 9, 2007
Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complexMichael Shara, Anthony E Kincaid, Aimee L Limpach, et al.Academic Medicine : Journal of the Association of American Medical Colleges|June 23, 2016
Striving for Gender Equity in Academic Medicine Careers: A Call to ActionCarol Bates, Lynn Gordon, Elizabeth Travis, et al.Academic Medicine : Journal of the Association of American Medical Colleges|August 1, 2013
Evolution of faculty affairs and faculty development offices in U.S. medical schools: a 10-year follow-up surveyRoberta E Sonnino, Vivian Reznik, Luanne A Thorndyke, et al.Current Medical Research and Opinion|December 6, 2023
The association between influenza vaccine effectiveness and egg-based manufacturing technology: literature review and US expert consensusArchana Chatterjee, Karita Ambrose, David H Canaday, et al.Human Vaccines|November 4, 2011
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 yearsMark H Einstein, Mira Baron, Myron J Levin, et al.The Pediatric Infectious Disease Journal|December 3, 2009
Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccineStan L Block, Darron R Brown, Archana Chatterjee, et al.Pageof 7